A young specialist explores a paradigm shift in the cyclical 'treat, respond, relapse, repeat' approach to therapy for ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in ...

Prakash Patel is currently undergoing chemotherapy for follicular lymphoma cancer and unexpectedly had his Lloyds bank account closed.